As neutrophil and lymphocyte counts are routinely conducted in clinical settings, the neutrophil-to-lymphocyte ratio (NLR) is one of most studied prognostic biomarkers for cancer progression and anti-cancer therapies including anti-PD-(L)1 immunotherapy [155,156]. The gene discussed is CD274; the disease is cancer.